Atorvastatin CalciumThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

1643 records returned

Pfizer submits new paediatric data for atorvastatin to European Medicines AgencyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: BioSpace Area: News Pfizer Inc has announced that it has submitted paediatric data for atorvastatin to the European Medicines Agency (EMEA) and also developed a new chewable form of the drug, including a paediatric-appropriate 5 mg dose, which is part of this submission. (Source: NeLM - Cardiovascular Medicine)
Source: NeLM - Cardiovascular Medicine - November 19, 2009 Category: Cardiology Source Type: organizations

Pfizer Submits New Pediatric Data For Lipitor(R) (Atorvastatin) To The European Medicines Agency (EMEA)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pfizer Inc (NYSE:PFE) announced it has submitted pediatric data for Lipitor® (atorvastatin) to the European Medicines Agency (EMEA). Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5 mg dose, which is part of this submission. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 18, 2009 Category: Consumer Health News Tags: Pediatrics / Children's Health Source Type: news

Pfizer Submits New Pediatric Data For Lipitor(R) (Atorvastatin) To The European Medicines Agency (EMEA)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pfizer Inc (NYSE:PFE) announced it has submitted pediatric data for Lipitor® (atorvastatin) to the European Medicines Agency (EMEA). Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5 mg dose, which is part of this submission. (Source: Cholesterol News From Medical News Today)
Source: Cholesterol News From Medical News Today - November 18, 2009 Category: Cardiology Tags: Pediatrics / Children's Health Source Type: news

Pfizer Inc Submits New Pediatric Data for Lipitor to EMEAEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
From EquityBites (November 18, 2009) Health care company Pfizer Inc (NYSE:PFE) declared on Wednesday the submission of paediatric data for Lipitor (atorvastatin) to the European Medicines Agency (EMEA). This follows the EMEA's conclusion that... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 18, 2009 Category: Pharmaceuticals Source Type: news

NicOx - NCX 6560 meets primary and secondary objectives in first-in-man studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sophia Antipolis, France, November 13, 2009 - NicOx S.A. (NYSE Euronext Paris: COX) today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

Stereoselective introduction of two chiral centers by a single diketoreductase: an efficient biocatalytic route for the synthesis of statin side chains.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Statins, including atorvastatin (Lipitor((R))), are the top-selling drugs in the world. The biocatalytic production of chiral side chains of statin drugs is of great interest to academia and industry. Stereoselective double reduction of a beta,delta-diketo ester catalyzed by a diketoreductase offers a simple and efficient route for the preparation of statin side chains. Comparison of different cofactor regeneration systems resulted in an easy and cost-effective process for this enzymatic reduction. PMID: 19916068 [PubMed - as supplied by publisher] (Source: Amino Acids)
Source: Amino Acids - November 16, 2009 Category: Biochemistry Authors: Wu X, Wang L, Wang S, Chen Y Tags: Amino Acids Source Type: journals

Atorvastatin: Cholestatic jaundice in an elderly patient: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 11, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Dr Reddy's files for marketing Lipitor genericEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dr Reddy's Laboratories has filed for marketing a generic version of Pfizer's cholesterol-lowering drug Lipitor in the US. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 7, 2009 Category: Pharmaceuticals Source Type: news

Highly stereoselective hydrogenations-As key-steps in the total synthesis of statins.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Statins are inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMG-CoA reductase) and became the standard of care for treatment of hypercholesterolemia because of their efficacy, safety, and long-term benefits. They are administered as diastereo- and enantiomerically pure compounds. We summarize here two new approaches for the total synthesis of the most important representatives, atorvastatin, and rosuvastatin, based on highly stereoselective hydrogenations as key-steps. Chirality 2010. (c) 2009 Wiley-Liss, Inc. PMID: 19899159 [PubMed - as supplied by publisher] (Source: Chirality)
Source: Chirality - November 6, 2009 Category: Molecular Biology Authors: Andrushko N, Andrushko V, Tararov V, Korostylev A, König G, Börner A Tags: Chirality Source Type: journals

Effect of atorvastatin on tumor growth and metastasis in a breast cancer cell xenograft model and its mechanismEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract This paper aims to evaluate the effects and the possible mechanisms of atorvastatin on tumor growth and metastasis in a xenograft tumor model. Twenty-four female athymic BALB/C mice with MDA-MB-435 xenograft tumors were randomly assigned to three groups: a control group, a low-dose atorvastatin treatment group, and a high-dose atorvastatin treatment group. The mice in the treatment groups began to be administered with atorvastatin (10 or 20 mg/kg per day) when the xenograft tumors reached 1 cm in diameter. At the end of the experiment, the tumor volume and weight and the lung metastasis colonies of ...
Source: Frontiers of Medicine in China - November 4, 2009 Category: Journals (General) Tags: Frontiers of Medicine in China Source Type: journals

The long-term effect between co-administration of simvastatin and ezetimibe and atorvastatin on central pulse wave velocity in adults with hypercholesterolemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The various statin might contribute to a change in arterial stiffness independent of the cholesterol-lowering effects of statin therapy. The aim of this study was to compare the short-term effect between co-administration of simvastatin and ezetimibe (vytorin) and atorvastatin (lipitor) on pulse wave velocity (PWV). (Source: Artery Research)
Source: Artery Research - November 2, 2009 Category: Cardiology Authors: Young Soo Lee, Kee Sik Kim, Myung Jun Seong, Jung Hyun Kim, So Yeon Kim, Jin Bae Lee, Jae keun Ryu, Ji Yong Choi, GUg Sung Chang Tags: Abstracts Source Type: journals

Achievement of ldl-c levels with three different drug strategies after failure of simvastatin 40mgEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Background: NICE lipid guidelines recommend simvastatin (S) 40mg as initial therapy, after lifestyle changes, in most patients requiring treatment. When desirable levels have not been met, increasing the dose, switching to a more potent statin or adding ezetimibe (E) can be considered. The addition of E to S was compared with switching to atorvastatin (A) or rosuvastatin (R) in a randomised, double-blind trial. (Source: Atherosclerosis)
Source: Atherosclerosis - November 1, 2009 Category: Cardiology Authors: T. McCormack, M. Blagden, R. Chipperfield, P. Harvey, R. Gaunt, S. Griffiths, P. Robinson Tags: HEART UK Annual Conference 2009 Abstracts Source Type: journals

[Effects of plasma containing Buyang Huanwu Decoction and its effective components and total Panax notoginseng saponins on vascular smooth muscle cell proliferation induced by platelet-derived growth factor.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: BYHWD and its alkaloids and glycosides have similar roles of resisting VSMC proliferation to TSPN and atorvastatin. Alkaloids and glycosides may be the major effective substances of anti-VSMC proliferation in BYHWD. PMID: 19912742 [PubMed - in process] (Source: Zhong xi yi jie he xue bao : Journal of Chinese Integrative Medicine.)
Source: Zhong xi yi jie he xue bao : Journal of Chinese Integrative Medicine. - November 1, 2009 Category: Complementary Medicine Authors: Li H, Chen G, Deng CQ Tags: Zhong Xi Yi Jie He Xue Bao Source Type: journals

Reduced Intimal Hyperplasia in Rabbits via Medical Therapy after Carotid Venous Bypass.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Intimal hyperplasia is a major cause of restenosis after the interventional or surgical treatment of occlusive arterial disease. We investigated the effects of clopidogrel, calcium dobesilate, nebivolol, and atorvastatin on the development of intimal hyperplasia in rabbits after carotid venous bypass surgery. We divided 40 male New Zealand rabbits into 4 study groups and 1 control group. After occluding the carotid arteries of the rabbits, we constructed jugular venous grafts between the proximal and the distal segments of the occluded artery. Thereafter, group 1 (control) received no medication. We administered daily ...
Source: Texas Heart Institute Journal - October 31, 2009 Category: Cardiology Authors: Yucel S, Bahcivan M, Gol MK, Erenler BH, Kolbakir F, Keceligil HT Tags: Tex Heart Inst J Source Type: journals

Study: Cholesterol drugs may improve flu survivalEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A new treatment for swine flu may already be on pharmacy shelves -- cholesterol-lowering statin drugs like Lipitor and Zocor. (Source: CTV Health)
Source: CTV Health - October 30, 2009 Category: Consumer Health News Source Type: news

Study: Cholesterol Drugs May Improve Flu SurvivalEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Doctors may have a new treatment for swine flu that's already on pharmacy shelves -- cholesterol-lowering statin drugs like Lipitor and Zocor. (Source: WDSU.com - Health)
Source: WDSU.com - Health - October 29, 2009 Category: Consumer Health News Authors: WDSU.com Source Type: news

Cholesterol-lowering statin drugs like Lipitor, Zocor, may improve flu survival, study findsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Doctors may have a new treatment for swine flu that's already on pharmacy shelves — cholesterol-lowering statin drugs like Lipitor and Zocor. A study released Thursday finds that people who were already on these drugs when they caught seasonal... (Source: OrlandoSentinel: Medical Research)
Source: OrlandoSentinel: Medical Research - October 29, 2009 Category: American Health Source Type: news

Ezetimibe Makes Atorvastatin More Efficient In Lowering Lipids In Men And Women Age 65 And OlderEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Adding ezetimibe to atorvastatin significantly boosted the attainment of lipid targets as specified by both Canadian and European guidelines in elderly patients aged 65 and older and the combination produced superior results than simply increasing the dose of atorvastatin alone, Dr. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 29, 2009 Category: Consumer Health News Tags: Heart Disease Source Type: news

Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafilEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
& E Amini (Source: International Journal of Impotence Research)
Source: International Journal of Impotence Research - October 29, 2009 Category: Urology & Nephrology Authors: F DadkhahM R SafarinejadM A AsgariS Y HosseiniA LashayE Amini Source Type: journals

Statistics on hospital prescribing in England 2008Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: NHS Information Centre Area: News The NHS Information Centre has published details of drug expenditure in hospitals in England 2008, including a table focussing on drugs positively appraised by NICE and comparing use of "low cost" drugs between SHAs. The overall NHS expenditure on medicines in 2008 was £11.6 billion and of the drugs positively appraised by NICE, the greatest overall cost was for atorvastatin but etanercept incurred the greatest cost in hospitals. (Source: NeLM - News)
Source: NeLM - News - October 29, 2009 Category: Drugs & Pharmacology Source Type: organizations

Atorvastatin improves response to treatment for erectile dysfunctionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Atorvastatin therapy improves the response to sildenafil of men with erectile dysfunction and hypercholesterolemia, report researchers. (Source: MedWire News - Lipidology)
Source: MedWire News - Lipidology - October 29, 2009 Category: Lipidology Source Type: news

In vitro interactions between primycin and different statins in their effects against some clinically important fungi.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The in vitro antifungal activities of primycin and various statins against some opportunistic pathogenic fungi were investigated. Primycin completely inhibited the growth of Candida albicans (MIC: 64 microg ml(-1)) and Candida glabrata (MIC: 32 microg ml(-1)), and was very effective against Paecilomyces variotii (MIC: 2 microg ml(-1)), but it had little effect on Aspergillus fumigatus, Aspergillus flavus or Rhizopus oryzae (MIC: >64 microg ml(-1)). The fungi exhibited different degrees of sensitivity to the statins; fluvastatin and simvastatin exerted potent antifungal activities against a wide variety of clinically...
Source: Journal of Medical Microbiology - October 29, 2009 Category: Microbiology Authors: Nyilasi I, Kocsube S, Pesti M, Lukacs G, Papp T, Vagvolgyi C Tags: J Med Microbiol Source Type: journals

Adding ezetimibe to atorvastatin improves lipid controlEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Heart and Stroke Foundation of Canada) Adding ezetimibe to atorvastatin significantly boosted the attainment of lipid targets as specified by both Canadian and European guidelines in elderly patients aged 65 and older and the combination produced superior results than simply increasing the dose of atorvastatin alone, Dr. Christian Constance told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 27, 2009 Category: Global & Universal Source Type: news

Adding Ezetimibe To Atorvastatin Improves Lipid Control, Study FindsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Adding ezetimibe to atorvastatin significantly boosted the attainment of lipid targets as specified by both Canadian and European guidelines in elderly patients aged 65 and older and the combination produced superior results than simply increasing the dose of atorvastatin alone, a new study shows. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 27, 2009 Category: Science Source Type: news

Pfizer’s Q3 income rose, despite lower Lipitor salesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pfizer has reported a double-digit increase in net income for the 2009 third quarter, despite falling cardiovascular pharmaceutical sales. (Source: Cardiovascular Business News)
Source: Cardiovascular Business News - October 26, 2009 Category: Cardiology Tags: Latest News Source Type: news

Occurrence and fate of rosuvastatin, rosuvastatin lactone, and atorvastatin in Canadian sewage and surface water samples.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Rosuvastatin (RST) and atorvastatin (ATO) are prescription drugs and members in the statin family used for the treatment of elevated cholesterol levels. A method using solid-phase extraction and liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the determination of ATO, RST and its metabolite rosuvastatin lactone (RSTL) in sewage and surface water samples has been developed. In the influent and effluent samples collected from 11 sewage treatment plants located in Ontario, Canada, ATO, RST, and RSTL were detected in all samples with median concentrations of 166ngL(-1) (influent) and 77ngL(-1) (effluent) for ...
Source: Chemosphere - October 26, 2009 Category: Chemistry Authors: Lee HB, Peart TE, Lewina Svoboda M, Backus S Tags: Chemosphere Source Type: journals

Lipitor and erectile dysfunctionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
My husband has high cholesterol. His doctor put him on Lipitor. After the dosage was increased, I noticed he wasn't as enthusiastic about our previously very active sex life. He said he wasn't feeling aroused and his usual morning erections weren't occurring. He asked his doctor if the Lipitor might be responsible, and the doc said to stop it for a month and see what happened. (Source: L.A. Times - Health)
Source: L.A. Times - Health - October 24, 2009 Category: Consumer Health News Source Type: news

A green-by-design biocatalytic process for atorvastatin intermediateEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Steven K. Ma, John Gruber, Chris Davis, Lisa Newman, David Gray, Alica Wang, John Grate, Gjalt W. Huisman, Roger A. Sheldon (Paper from Green Chem.) Steven K. Ma, Green Chem., 2010, DOI: 10.1039/b919115c To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Green Chem. latest articles)
Source: RSC - Green Chem. latest articles - October 22, 2009 Category: Chemistry Authors: Steven K. MaJohn Gruber Chris Davis Lisa Newman David Gray Alica Wang John Grate Gjalt W. Huisman Roger A. Sheldon Source Type: journals

Natural History of Markers of Collagen Turnover in Patients With Early Diastolic Dysfunction and Impact of EplerenoneEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: This study demonstrates progressive increases in markers of collagen turnover and inflammation in HFPSF with diastolic dysfunction. Despite high background utilization of renin-angiotensin-aldosterone modulators, eplerenone therapy prevents a progressive increase in pro-collagen type-III aminoterminal peptide and may have a role in management of this disease. (The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart Failure; NCT00505336) (Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - October 22, 2009 Category: Cardiology Authors: George J. Mak, Mark T. Ledwidge, Chris J. Watson, Dermot M. Phelan, Ian R. Dawkins, Niamh F. Murphy, Anil K. Patle, John A. Baugh, Kenneth M. McDonald Tags: Clinical Research Source Type: journals

Chantix slash costsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The maker of Lipitor, Viagra and anti-smoking drug Chantix is $2.88 billion in the black after slashing costs (Source: Pharmacy Europe)
Source: Pharmacy Europe - October 21, 2009 Category: Drugs & Pharmacology Source Type: news

Quantitation of atorvastatin in human plasma using directly suspended acceptor droplet in liquid-liquid-liquid microextraction and high-performance liquid chromatography-ultraviolet detection.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A simple and sensitive methodology based on liquid-liquid-liquid microextraction (LLLME) followed by high-performance liquid chromatography-ultraviolet detection (HPLC-UV) has been successfully developed for the determination of atorvastatin (AT) in human plasma. AT was first extracted from 4.5mL acidic aqueous sample (diluted plasma, donor phase, pH 1) at temperature 45 degrees C through 400muL 1-octanol for 4.5min, while being agitated by a stirring bar at 1250rpm. Then, a 5.5muL free suspended basic aqueous droplet (acceptor phase, pH 10) was delivered to the top-center position of the organic membrane. The mixture ...
Source: Talanta - October 21, 2009 Category: Chemistry Authors: Farahani H, Norouzi P, Beheshti A, Sobhi HR, Dinarvand R, Ganjali MR Tags: Talanta Source Type: journals

Pfizer Profit Jumps 26%Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pfizer's profit rose 26% as cost cutting helped fight competition from generic drugs to sales of its blockbuster cholesterol-treatment, Lipitor. (Source: WSJ.com: Health)
Source: WSJ.com: Health - October 20, 2009 Category: Pharmaceuticals Tags: PAID Source Type: news

Drugmaker Pfizer's 3Q profit jumps 26 percent on cost cuts; more expected with Wyeth deal doneEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
TRENTON, N.J. (AP) — Drugmaker Pfizer Inc. on Tuesday posted a 26 percent jump in third-quarter profit despite the recession, as sharp cost cuts made up for a dip in sales. The maker of cholesterol fighter Lipitor, impotence treatment Viagra and... (Source: OrlandoSentinel: Medical Research)
Source: OrlandoSentinel: Medical Research - October 20, 2009 Category: American Health Source Type: news

Effect of preoperative atorvastatin therapy on paraoxonase activity and oxidative stress after coronary artery bypass grafting.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, 15 days of preoperative atorvastatin therapy does not significantly change either the serum PON1 activity or the oxidative stress after CABG. PMID: 19843623 [PubMed - as supplied by publisher] (Source: Perfusion)
Source: Perfusion - October 19, 2009 Category: Cardiovascular & Thoracic Surgery Authors: Kurban S, Mehmetoglu I, Ege E Tags: Perfusion Source Type: journals

Pfizer to pay $1.3 billion criminal fine for misbranding its drugsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(NaturalNews) In the largest criminal fine ever levied against any drug company in the world, a unit of U.S.-based Pfizer, Inc. was sentenced to pay $1.3 billion in criminal fines and revenue forfeiture. It's all part of a $2.3 billion settlement announced by the Justice Department. The case centers around Pfizer's criminal "off-label marketing" of four drugs, including the painkiller Bextra. After whistleblowers filed lawsuits in three states, the U.S. Justice Department took an interest in the case and prosecuted Pfizer for criminal acts.In the settlement, Pfizer admitted to a felony crime and agreed to pay $2.3 billion ...
Source: NaturalNews.com - October 19, 2009 Category: Consumer Health Advice Source Type: news

A 47-year-old female with ulcerated lesionsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A 47-year-old African American female presented to our department for the evaluation of a large ulcerated lesion on her left wrist and a similar lesion on the right side of the base of her skull that had been present for 1 and a half years and 1 year, respectively. Both lesions began as small papules and had progressively increased in size. The patient denied any recent trauma to the areas, any previous similar lesions, and stated that the lesions did not bleed or cause pain. Her medical history was significant for rheumatic fever, hypertension, and dyslipidemia. Her medications include hydrochlorothiazide, atorvastatin, l...
Source: Journal of the American Academy of Dermatology - October 17, 2009 Category: Dermatology Authors: Alison Trappey, Sarah Glorioso, Gaston de la Bretonne Tags: JAAD Grand Rounds Source Type: journals

The SLCO1B1*5 Genetic Variant Is Associated With Statin-Induced Side EffectsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: SLCO1B1*5 genotype and female sex were associated mild statin-induced side effects. These findings expand the results of a recent genome-wide association study of statin myopathy with CK >3× normal to milder, statin-induced, muscle side effects. (Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - October 16, 2009 Category: Cardiology Authors: Deepak Voora, Svati H. Shah, Ivan Spasojevic, Shazia Ali, Carol R. Reed, Benjamin A. Salisbury, Geoffrey S. Ginsburg Tags: Genetics and Statin Effects Source Type: journals

Statins Making Comeback in Multiple SclerosisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
After the failure of atorvastatin, many speculated enthusiasm for statins in multiple sclerosis would wane, but researchers say it is too soon to rule them out. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 14, 2009 Category: Consumer Health News Tags: Neurology & Neurosurgery Source Type: news

CVN: Heart MinuteEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Heart Minute: Lipitor in PCI (Source: Cardiosource)
Source: Cardiosource - October 13, 2009 Category: Cardiology Source Type: organizations

Effect of Preoperative Atorvastatin Therapy on Atrial Fibrillation Following Off-Pump Coronary Artery Bypass Grafting.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Administration of atorvastatin 20 mg/day, initiated 1 week before elective off-pump CABG and continued in the postoperative period, significantly decreases postoperative AF. PMID: 19822977 [PubMed - as supplied by publisher] (Source: Circulation Journal)
Source: Circulation Journal - October 12, 2009 Category: Cardiology Authors: Ji Q, Mei Y, Wang X, Sun Y, Feng J, Cai J, Xie S, Chi L Tags: Circ J Source Type: journals

18F-4V for PET-CT Imaging of VCAM-1 Expression in AtherosclerosisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions 18F-4V allows noninvasive PET-CT imaging of VCAM-1 in inflammatory atherosclerosis, has the dynamic range to quantify treatment effects, and correlates with inflammatory gene expression. (Source: Journal of the American College of Cardiology: Cardiovascular Imaging)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - October 12, 2009 Category: Radiology Authors: Nahrendorf, M., Keliher, E., Panizzi, P., Zhang, H., Hembrador, S., Figueiredo, J.-L., Aikawa, E., Kelly, K., Libby, P., Weissleder, R. Tags: Original Research Source Type: journals

Antineoplastics/atorvastatin/entecavir: Hepatitis B virus reactivation and liver injury: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 6, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Atorvastatin/colchicine interaction: Acute neuromyopathy in an elderly patient with renal failure: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 6, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Pleiotropic Effects of Atorvastatin on Monocytes in Atherosclerotic Patients.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The objective of this study was to investigate the gene expression signature of monocyte/macrophages and the pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients. Forty patients with coronary heart diseases were randomly assigned to double-blind therapy with either 20 or 80 mg per day of atorvastatin. Follow-up visits occurred at weeks 6 and 12, including complete chemistry and lipid analyses and quantification of 14 target genes in monocytes. After 12 weeks of therapy, both groups gained beneficial alterations in lipid profiles. Both groups experienced significant reductions in gene expression of l...
Source: The Journal of Clinical Pharmacology - October 5, 2009 Category: Drugs & Pharmacology Authors: Wang ZH, Liu XL, Zhong M, Zhang LP, Shang YY, Hu XY, Li L, Zhang Y, Deng JT, Zhang W Tags: J Clin Pharmacol Source Type: journals

Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Simvastatin and atorvastatin are metabolized by the CYP3A4 enzyme and transported by the ABCB1 transporter. We studied whether the polymorphism CYP3A4*1B and the polymorphisms C1236T, G2677A/T and C3435T in the ABCB1 gene were associated with a decrease of the prescribed dose or a switch to another cholesterol lowering drug during simvastatin and atorvastatin therapy. These events may indicate that statin plasma levels were too high and resulted in an adverse drug reaction or a too strong reduction in cholesterol level.We identified 1239 incident simvastatin and atorvastatin users in the Rotterdam Study, a population-based...
Source: Pharmacoepidemiology and Drug Safety - October 2, 2009 Category: Drugs & Pharmacology Authors: Matthijs L. Becker, Loes E. Visser, Ron H. N. van Schaik, Albert Hofman, André G. Uitterlinden, Bruno H. Ch. Stricker Source Type: journals

Actavis launches challenge to Pfizer drugEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The introduction of a cheaper variant of Lipitor in the market marks an important threat to Pfizer amid the continuing competition between generic companies and the originator pharmaceutical groups (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 2, 2009 Category: Pharmaceuticals Source Type: news

Actavis' clients launch first generic Atorvastatin in SpainEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Actavis Group today announced that its third-party sales division, Medis, has delivered 30 million tablets of Atorvastatin to its clients in Spain (Source: Pharmacy Europe)
Source: Pharmacy Europe - October 1, 2009 Category: Drugs & Pharmacology Source Type: news

Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: FMT-CT is a robust and observer-independent tool for noninvasive assessment of inflammatory murine atherosclerosis. Reporter-containing nanomaterials may have unique advantages over small molecule agents for in vivo imaging. PMID: 19608968 [PubMed - indexed for MEDLINE] (Source: Arteriosclerosis, Thrombosis and Vascular Biology)
Source: Arteriosclerosis, Thrombosis and Vascular Biology - September 30, 2009 Category: Cardiology Authors: Nahrendorf M, Waterman P, Thurber G, Groves K, Rajopadhye M, Panizzi P, Marinelli B, Aikawa E, Pittet MJ, Swirski FK, Weissleder R Tags: Arterioscler Thromb Vasc Biol Source Type: journals

Early Statin Therapy in Acute Coronary Syndromes: The Successful Cycle of Evidence, Guidelines, and ImplementationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
That statins should be prescribed for patients before hospital discharge after an episode of acute coronary syndrome (ACS) is a Level of Evidence: 1A recommendation of the American College of Cardiology/American Heart Association Joint Task Force. This level of recommendation is based upon 2 clinical trials: the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) and PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) trials. In the MIRACL trial, 3,086 patients with unstable angina or non–Q-wave myocardial infarction were randomized within 4 days of the event to atorvastatin 80...
Source: Journal of the American College of Cardiology - September 30, 2009 Category: Cardiology Authors: David D. Waters, Ivy Ku Tags: VIEWPOINT AND COMMENTARY Source Type: journals